^
    Back
    Association details:
    Biomarker:HR negative
    Cancer:HER2 Negative Breast Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Published date:
    11/24/2021
    Excerpt:
    HR-Negative/HER2-Negative disease...For high-risk: Adjuvant pembrolizumab (if pembrolizumab-containing regimen was given preoperatively)
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

    Excerpt:
    ...- Breast cancer determined to be hormone receptor-positive or hormone receptor-negative defined as follows:...
    Trial ID:
    NCT02957968